SAB Biotherapeutics announces management participation in February investor conferences, discussing their clinical-stage therapies for autoimmune diseases.
Quiver AI Summary
SAB Biotherapeutics, Inc. announced that its management team will participate in two investor conferences in February 2026: the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. Both events will feature fireside chats, with the latter being virtual. SAB Biotherapeutics is focused on developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes and other autoimmune diseases, utilizing proprietary technology to produce human immunoglobulins without human donors. Their lead candidate, SAB-142, aims to modify the treatment approach for autoimmune T1D. For more information, the company invites interested parties to visit their website.
Potential Positives
- Company's participation in two prominent investor conferences signals confidence and increased visibility in the biotech sector.
- Focus on developing innovative therapies for type 1 diabetes and autoimmune disorders positions SAB Biotherapeutics as a leader in addressing significant unmet medical needs.
- Use of advanced genetic engineering and proprietary technology highlights the company's commitment to innovative solutions in therapeutic development.
Potential Negatives
- Participation in investor conferences may indicate a need for external funding or support, which can be perceived as a sign of financial instability or dependency.
- The company's focus on developing innovative treatments for autoimmune diseases suggests that they operate in a highly competitive and uncertain market, which can pose significant risks to their future success.
- The absence of detailed information regarding the success or status of their lead candidate, SAB-142, may raise concerns about the viability and progress of their development efforts.
FAQ
What is SAB Biotherapeutics focused on?
SAB Biotherapeutics specializes in developing human anti-thymocyte immunoglobulin for type 1 diabetes and autoimmune diseases.
When will SAB Biotherapeutics participate in investor conferences?
SAB Biotherapeutics will participate in two conferences in February 2026, on the 11th and 25th.
Where can I access the live webcast of the investor events?
The live webcast and archived recording can be accessed on the Investors & Media section of SAB Bio's website.
What is SAB-142?
SAB-142 is SAB Biotherapeutics' lead candidate targeting autoimmune type 1 diabetes with a disease-modifying therapeutic approach.
How does SAB Biotherapeutics develop its therapies?
SAB Biotherapeutics uses advanced genetic engineering and antibody science to create therapies without relying on human donors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SABS Hedge Fund Activity
We have seen 19 institutional investors add shares of $SABS stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIVO CAPITAL, LLC added 11,420,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $22,954,199
- RA CAPITAL MANAGEMENT, L.P. added 4,401,500 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,847,014
- COMMODORE CAPITAL LP added 4,401,500 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,847,014
- WOODLINE PARTNERS LP added 2,850,881 shares (+inf%) to their portfolio in Q3 2025, for an estimated $5,730,270
- SESSA CAPITAL IM, L.P. added 1,740,000 shares (+379.5%) to their portfolio in Q3 2025, for an estimated $3,497,399
- VANGUARD GROUP INC added 1,481,383 shares (+405.0%) to their portfolio in Q4 2025, for an estimated $5,540,372
- SPHERA FUNDS MANAGEMENT LTD. added 566,395 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,138,453
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SABS Analyst Ratings
Wall Street analysts have issued reports on $SABS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- Chardan Capital issued a "Buy" rating on 11/17/2025
To track analyst ratings and price targets for $SABS, check out Quiver Quantitative's $SABS forecast page.
$SABS Price Targets
Multiple analysts have issued price targets for $SABS recently. We have seen 4 analysts offer price targets for $SABS in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Michael Yee from UBS set a target price of $7.0 on 01/07/2026
- Yatin Suneja from Guggenheim set a target price of $15.0 on 12/19/2025
- Keay Nakae from Chardan Capital set a target price of $12.0 on 12/18/2025
- An analyst from Leerink Partners set a target price of $7.0 on 09/17/2025
Full Release
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February:
Guggenheim Securities Emerging Outlook: Biotech Summit
Date:
February 11, 2026
Time: 10:30 a.m. ET
Format:
Fireside Chat
Location: New York, NY
Oppenheimer 36
th
Annual Healthcare Life Sciences Conference
Date:
February 25, 2026
Time: 8:40 a.m. ET
Format:
Fireside Chat
Location: Virtual
To access a live webcast of these events, as well as an archived recording, please visit the
Investors & Media
section of the Company’s website at
www.sab.bio
.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit
www.sab.bio
.
CONTACTS
Investors:
Cristi Barnett
[email protected]
Media:
Sheila Carlson
[email protected]
